EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer

Stock Information for EDAP TMS S.A.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About EDAP TMS S.A.

EDAP Announces Corporate Name Change to FocalTherics(TM) to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
EDAP | Focal One to Host Investor Day on June 1, 2026
EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue
EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.